Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic
  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

CLASS ACTION UPDATE for CRMD, KPLT and ANVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / September 14, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

CRMD Shareholders Click Here: https://www.zlk.com/pslra-1/cormedix-inc-loss-submission-form?prid=19571&wire=1
KPLT Shareholders Click Here: https://www.zlk.com/pslra-1/katapult-holdings-inc-information-request-form?prid=19571&wire=1
ANVS Shareholders Click Here: https://www.zlk.com/pslra-1/annovis-bio-inc-loss-submission-form?prid=19571&wire=1

* ADDITIONAL INFORMATION BELOW *

CorMedix Inc. (NASDAQ:CRMD)

CRMD Lawsuit on behalf of: investors who purchased July 8, 2020 - May 13, 2021
Lead Plaintiff Deadline : September 20, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cormedix-inc-loss-submission-form?prid=19571&wire=1

According to the filed complaint, during the class period, CorMedix Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Katapult Holdings, Inc. (NASDAQ:KPLT)

KPLT Lawsuit on behalf of: investors who purchased December 18, 2020 - August 10, 2021
Lead Plaintiff Deadline : October 26, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/katapult-holdings-inc-information-request-form?prid=19571&wire=1

According to the filed complaint, during the class period, Katapult Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) despite Katapult's assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers' future buying behavior; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Annovis Bio, Inc. (NYSE:ANVS)

ANVS Lawsuit on behalf of: investors who purchased May 21, 2021 - July 28, 2021
Lead Plaintiff Deadline : October 18, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/annovis-bio-inc-loss-submission-form?prid=19571&wire=1

According to the filed complaint, during the class period, Annovis Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/664009/CLASS-ACTION-UPDATE-for-CRMD-KPLT-and-ANVS-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.